ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within a week after starting therapy, with improvements continuing out to 3 months, in a global phase 3 clinical trial...
GET PAID FOR SHOPPING AT ALL YOUR FAVORITE STORES!
Sound too good to be true? Here’s the deal: Stores pay us a commission for sending you their way.
We share that with you as Cash Back. Everyone wins! SIGN UP FOR FREE!
.png)
COOL ROOM ENTERTAINMENT 10530 Campus Way South #1174 Largo, MD 20774
(916) 619-1308
teosmoot@gmail.com
Copyright © 2024 Cool Room Entertainment. All Rights Reserved
